Clomiphene and HCG for hypogonadism: what the pituitary axis evidence actually says

Most conversations about low testosterone jump straight to injections or gels. That is not often the wrong answer -- but it is often the first answer when it should be the third or fourth. Before you replace testosterone from the outside, it is worth asking whether your body can be prompted to make more of its own. That is exactly what clomiphene citrate and human chorionic gonadotropin (HCG) are designed to do, and a 2025 cohort study published on PubMed (https://pubmed.ncbi.nlm.nih.gov/42402873/) offers some of the clearest recent data on how they each affect the pituitary axis and how their effectiveness compares in real-world patients.

If you have read our overview on understanding testosterone replacement therapy or our piece on signs of low testosterone, you already know that diagnosis comes before treatment. This post goes one level deeper -- into the physiology of the axis itself and what that means for which medication makes sense for which person.

Why the pituitary axis matters before you pick a protocol

Testosterone does not operate in isolation. It is the output of a signaling chain that starts in the brain. The hypothalamus releases GnRH (gonadotropin-releasing hormone), which tells the pituitary to release LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH signals the testes to produce testosterone. FSH supports sperm production. The whole system is called the hypothalamic-pituitary-gonadal (HPG) axis, and understanding where it breaks down is the difference between a diagnosis and a lab number.

Hypogonadism comes in two main forms. Primary hypogonadism means the problem is in the testes -- they cannot respond adequately even when LH is high or normal. Secondary hypogonadism (also called hypogonadotropic hypogonadism) means the signal from the brain is too weak, so LH and FSH are low or inappropriately normal, and the testes -- which are capable of working -- simply are not being told to. This distinction matters enormously for treatment, because clomiphene and HCG are only useful when the testes are still capable of responding.

The 2025 cohort study followed men on clomiphene and men on HCG and tracked not just testosterone levels but the full pituitary response -- including LH, FSH, and estradiol -- over time. The findings confirm what smaller studies have suggested: both agents can raise testosterone meaningfully in secondary hypogonadism, but they do so through different mechanisms and with different hormonal footprints.

How clomiphene works -- and what the data shows

Clomiphene citrate (sold under brand names including Clomid) was developed for female infertility, but its use in men has been studied for decades. It is a selective estrogen receptor modulator (SERM). In plain terms, it blocks estrogen receptors in the hypothalamus and pituitary, which causes the brain to interpret estrogen levels as low. The response is to increase GnRH pulse frequency, which drives up LH and FSH, which in turn tells the testes to produce more testosterone.

Because clomiphene works at the top of the axis rather than at the testes, it raises both LH and FSH -- the full gonadotropin signal. This is clinically significant because FSH is what drives spermatogenesis. Men who want to preserve or restore fertility while treating low testosterone are often best served by an approach that keeps FSH active. Standard TRT suppresses both LH and FSH entirely.

A 2019 study in the Journal of Urology (https://pubmed.ncbi.nlm.nih.gov/31136724/) followed men on clomiphene for a median of 34 months and found that most maintained testosterone levels in the normal range with stable LH and FSH responses. Testosterone roughly doubled from baseline in responders. A smaller earlier study (https://pubmed.ncbi.nlm.nih.gov/22458540/) found similar durability at up to three years with an acceptable side-effect profile.

The 2025 cohort study adds important detail: clomiphene's effect on the pituitary is robust and sustained, but the degree of LH and FSH elevation it produces varies substantially between individuals. Men with more severe axis suppression -- meaning very low baseline LH -- tend to respond less predictably. Estradiol also rises alongside testosterone in many men on clomiphene, which requires monitoring. If estradiol climbs too high, it can counteract some of the benefits and cause symptoms of its own.

The practical takeaway: clomiphene is a reasonable first-line option for secondary hypogonadism in men who want to preserve fertility, who have baseline LH and FSH that are low but not absent, and who are willing to have estradiol checked alongside testosterone at follow-up visits.

How HCG works -- and where it fits differently

HCG is a hormone that structurally resembles LH closely enough that it binds to the same receptors on Leydig cells in the testes. When you inject HCG, you are effectively delivering the signal that the pituitary was failing to send. The testes respond by producing testosterone -- and, as a byproduct, estradiol, because HCG also stimulates aromatization.

Because HCG acts at the testicular level and bypasses the hypothalamus and pituitary entirely, it does not raise FSH. That is an important distinction. Men on HCG alone will see testosterone rise, but FSH remains wherever it was before treatment. For men whose primary concern is fertility, this is a limitation -- FSH is still needed for sperm production. In practice, HCG is sometimes paired with FSH injections or used alongside clomiphene when both sperm production and testosterone are goals.

HCG is also the agent most commonly added to standard TRT protocols when a man on testosterone injections wants to preserve testicular function or size. Because exogenous testosterone suppresses LH completely, the testes shrink and stop producing testosterone of their own without stimulation. Adding low-dose HCG mimics the LH signal, keeping the testes active even while TRT is ongoing (https://pubmed.ncbi.nlm.nih.gov/11925389/).

The 2025 cohort data shows that HCG raises testosterone effectively in secondary hypogonadism and does so with a different pituitary impact than clomiphene -- specifically, it does not increase LH or FSH (since it bypasses the pituitary), and it tends to produce a more pronounced rise in estradiol relative to testosterone in some men. This is not a reason to avoid it, but it is a reason to monitor estradiol carefully and to understand that the hormonal pattern on HCG looks different from the pattern on clomiphene or TRT.

What the 2025 cohort study adds to clinical decision-making

The study is one of the more granular real-world comparisons of these two agents in a single cohort. Both clomiphene and HCG were effective at raising testosterone from hypogonadal to normal ranges, but the hormonal environment they created differed. Clomiphene produced a more physiologic-looking axis response -- LH and FSH both elevated, estradiol rising in proportion to testosterone. HCG produced testosterone without engaging the pituitary, which means the hormonal pattern is less physiologic in one sense (no FSH signal) but may be more desirable in specific scenarios -- particularly when someone is already on TRT and HCG is being used as an adjunct.

Neither agent is universally superior. What the data supports is matching the agent to the clinical picture: where the axis is broken, what the fertility goals are, and how the individual responds to monitoring at follow-up. This is exactly why a real evaluation -- with two morning testosterone draws, an LH, FSH, estradiol, prolactin, and thyroid panel -- matters before any treatment decision is made. The AUA guidelines (https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline) and the Endocrine Society clinical practice guideline (https://pubmed.ncbi.nlm.nih.gov/29562364/) both emphasize this workup, and the 2025 cohort findings reinforce why skipping it leads to mismatched treatment.

For a deeper look at how clomiphene response can be predicted from baseline lab patterns, our post on predictors of clomiphene citrate response covers that evidence in detail.

When neither clomiphene nor HCG is the right choice

It is worth being direct about the limits of these agents. Neither works in primary hypogonadism -- if the testes cannot respond to LH, giving more LH signal (via HCG) or more LH signal from the pituitary (via clomiphene) will not help. Men with Klinefelter syndrome, prior testicular injury, or post-orchitis hypogonadism typically have high LH and FSH already, and the problem is testicular failure rather than signaling failure. In those cases, TRT is the appropriate route.

Clomiphene also carries a warning about visual disturbances that must be taken seriously. Any change in vision while on clomiphene should prompt stopping the medication and contacting a clinician immediately. Mood changes, particularly irritability or low mood, are also reported and worth discussing at follow-up.

If your testosterone is low and your symptoms are real but your labs show high LH and FSH, you already have the answer: the pituitary is doing its job and the testes are not keeping up. Stimulating an already-stimulated system is unlikely to help and may complicate the picture. That is a conversation worth having explicitly at the time of diagnosis -- not after three months on a medication that cannot work for your physiology.

How we approach this at NoMi Beach Health

When a man comes to us with symptoms of low testosterone -- low libido, fatigue in the specific clinical sense (not just life fatigue), loss of morning erections, declining lean mass -- we do not start with a treatment plan. We start with a workup.

That means two morning testosterone draws on separate days, plus LH, FSH, estradiol, prolactin, thyroid panel, complete blood count, and PSA in men over 40. We look for reversible causes -- sleep apnea, obesity, opioid use, elevated prolactin from a pituitary adenoma -- because treating those can restore testosterone without any medication at all.

If the workup points to secondary hypogonadism -- low testosterone with low or inappropriately normal LH and FSH, and no reversible cause -- we have a real conversation about options. If fertility matters now or in the future, clomiphene or HCG (or a combination) moves to the front of the list before TRT is even discussed. If someone is already on TRT from another provider and wants to know whether HCG makes sense as an adjunct, that is a different conversation with a different answer.

We recheck labs at six weeks and three months. We adjust based on data, not assumptions. And we tell you when something is not working.

For more on how we think about men's hormonal health across the arc of your 30s, 40s, and beyond, read our guide on concierge men's health after 35.

---

If low testosterone has been on your mind -- or if you have been on a protocol somewhere else and want a second opinion grounded in your actual lab data -- we would like to talk. Book a new-patient visit at the men's health services page or call us at (786) 744-5152. We will look at the full picture, explain what the evidence actually supports, and build a plan you can defend on paper.